AMRX — Amneal Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $2.34bn
- $4.84bn
- $2.79bn
- 66
- 86
- 68
- 86
Annual cashflow statement for Amneal Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 68.6 | 20.2 | -255 | -48.7 | -73.9 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 136 | 122 | 140 | 212 | 137 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -61.3 | -134 | -59.9 | -47.2 | -4.07 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | 379 | 242 | 65.1 | 346 | 295 |
| Capital Expenditures | -66.2 | -52.6 | -90.6 | -69.2 | -75 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -251 | -142 | -83.7 | 0 | 12 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -318 | -194 | -174 | -69.2 | -63 |
| Financing Cash Flow Items | -11.5 | -59.8 | -69 | -236 | -27.8 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 132 | -138 | -107 | -213 | -212 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 194 | -90.4 | -222 | 63.9 | 19.3 |